Brought to you by 
Allergan gets European rights to Ironwood's linaclotide; later expands agreement
01 Feb 2023
Executive Summary
Ironwood Pharmaceuticals Inc. licensed Allergan PLC exclusive rights to develop and commercialize the gastrointestinal therapy Constella (linaclotide) in the EU, Switzerland, Turkey, and the Commonwealth of Independent States.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Allergan gets European rights to Ironwood's linaclotide; later expands agreement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice